Cargando…
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control,...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770622/ https://www.ncbi.nlm.nih.gov/pubmed/24039399 http://dx.doi.org/10.2147/DDDT.S32331 |